Tempus announces 18 abstracts accepted for presentation at the american association for cancer research annual meeting 2025

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the american association for cancer research (aacr) annual meeting 2025, on april 25 - 30 in chicago. tempus researchers will showcase scientific and clinical research that highlight the transformative impact of ai on oncology treatment an.
TEM Ratings Summary
TEM Quant Ranking